Interestingly, abnormally high levels of serum B2M were detected in most MM patients and thus are considered a biomarker for staging and prognosis of MM18; nevertheless, the role of LILRB1 in MM has been poorly studied. This evidence concerns the gene LILRB1 and Miyoshi myopathy.